Transcriptomics

Dataset Information

0

Ilicicolin-A exert antitumor effect in CRPCa via suppressing EZH2 signaling pathway


ABSTRACT: Enhancer of zeste homolog 2 (EZH2) has critical roles in prostate cancer (PCa) progression and drug-resistance, which remains an obstacle for PCa treatment. Enzalutamide (ENZ) is a second-generation androgen receptor (AR) antagonist employed for treatment of metastatic castration-resistant prostate cancer (mCRPCa). A considerable proportion of tumors eventually develop resistance during treatment. Thus, agents that can overcome resistance to PCa are needed urgently. Ilicicolinal A (Ili-A), an ascochlorin derivative isolated from the coral-derived fungus Acremonium sclerotigenum GXIMD 02501, shows activity in human PCa cells, but its mechanism of action against CRPCa is not known. Here, RNA-sequencing showed the EZH2 pathway to be involved in PCa proliferation. Ili-A at low doses inhibited the transcriptional activity of EZH2 and AR targets by changing their protein expression. Interestingly, Ili-A suppressed the binding of EZH2 to promoter regions in AR/serine/threonine polo-like kinase-1/aurora kinase A. Moreover, low-dose Ili-A showed a synergistic effect with enzalutamide to inhibit survival of CRPCa cells in vitro, and enhanced the anti-cancer effect of enzalutamide on CRPCa xenografts with minimal side-effects. These data suggest that Ili-A could be used in combination with enzalutamide to treat CRPCa.

ORGANISM(S): Homo sapiens

PROVIDER: GSE182064 | GEO | 2021/08/20

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-09-07 | GSE211856 | GEO
2017-09-11 | GSE103449 | GEO
2016-03-08 | E-GEOD-72483 | biostudies-arrayexpress
2016-06-10 | E-GEOD-69896 | biostudies-arrayexpress
2016-02-24 | E-GEOD-78201 | biostudies-arrayexpress
2020-08-20 | GSE136129 | GEO
2020-08-20 | GSE136128 | GEO
2015-01-01 | GSE55345 | GEO
2021-10-05 | GSE185223 | GEO
2022-10-14 | PXD032041 | Pride